Ischemic Stroke Clinical Trial
— COSSOOfficial title:
Observational Study on the Certainty of Stroke Symptom Onset
NCT number | NCT01928641 |
Other study ID # | COSSO |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | August 2013 |
Est. completion date | August 2014 |
Verified date | January 2019 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Intravenous tissue plasminogen activator (IV t-PA) is the only proven treatment of hyperacute
cerebral infarction. The outcome of this treatment highly depends on the time from symptom
onset to the administration of thrombolytic agent. Last known normal time is widely used as
the standard to determine the symptom onset. These stroke symptoms are usually caused by a
sudden decrease in cerebral blood flow related with an embolic or thrombotic event. However,
in some cases various symptoms may occur one after another.
Myocardial infarction is also caused by a sudden caseation of blood flow. The symptom of
myocardial infarction usually contains chest pain, and it is easy to identify the exact time
of onset. In contrast, cerebral infarction may cause various symptoms according to the
infarcted area of the brain, and sometimes multiple symptoms are presented in rapid
succession. Therefore, it may be much unclear and uncertain to determine the onset time of
cerebral infarction. Despite the importance of onset time in therapeutic decision making,
there was no study focusing on the certainty of onset time in cerebral infarction patients.
In this study, we will investigate the subjective certainty of patient about the onset time
in clear-onset cerebral ischemia. The discrepancy in diagnosing the onset time will be
analyzed among the clinicians involved in the practice. Then, the factors associated with
this uncertainty will be verified.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | August 2014 |
Est. primary completion date | June 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - ischemic stroke patients admitted to Acute Stroke Unit at Asan Medical Center - ischemic stroke patients older than 20 years old - symptom onset within 24 hours Exclusion Criteria: - patients who cannot explain the symptom onset due to altered consciousness, aphasia, or cognitive decline |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Dong-Wha Kang | Seoul |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Discrepancy (difference) in the time onset of stroke symptoms diagnosed by two different neurologists | The onset time assessed at emergency departement by a neurologist will be compared to the onset time assessed next day after admission by a different neurologist. | Onset time will be obtained two times,first at the visit time of emergency department (within 24 hours from onset) and secondly the day after admission (within 48 hours from onset) | |
Secondary | Factors influencing the subjective uncertainty of stroke symptom onset by patients | The subjective uncertainty of the stroke symptom onset will be analyzed based on numerical scale from 1 to 5. Factors influencing the uncertainty will be investigated. Demographic factors, risk factors, stroke subtype, symptoms of stroke will be compared between patients with different certainty to stroke symptom onset |
The subjective certainty will be obtained the day after admission (within 48 hours from onset) | |
Secondary | Factor influencing the objective discrepancy of stroke symptom onset diagnosed by two different neurologists | Demographic factors, risk factors, stroke subtype, symptoms of stroke will be compared between patients with and without discrepancy on symptom onset of stroke diagnosed by two different neurologists | The factors will be obtained the day after admission (within 48 hours from symptom onset) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 |